Next Article in Journal
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival
Previous Article in Journal
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer
Previous Article in Special Issue
Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments
 
 
Article
Peer-Review Record

Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)

Cancers 2024, 16(3), 558; https://doi.org/10.3390/cancers16030558
by Bernd Kasper 1,*, Daniel Pink 2,3, Christian Rothermundt 4, Stephan Richter 5, Marinela Augustin 6, Attila Kollar 7, Annegret Kunitz 8, Wolfgang Eisterer 9, Verena Gaidzik 10, Thomas Brodowicz 11, Gerlinde Egerer 12, Peter Reichardt 13, Peter Hohenberger 14 and Markus K. Schuler 5,15
Reviewer 1:
Reviewer 2:
Cancers 2024, 16(3), 558; https://doi.org/10.3390/cancers16030558
Submission received: 29 December 2023 / Revised: 25 January 2024 / Accepted: 26 January 2024 / Published: 28 January 2024

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors Ok,to be published

 

Author Response

Thanks for your kind evaluation of our manuscript and the positive comments. No revisions needed.

Reviewer 2 Report

Comments and Suggestions for Authors

The authors have made a credible response to reviewer comments.

Line 412 is confusing - please rephrase - perhaps delete  "as some of the results are still contradictory" ?

Author Response

As recommende we have deleted the statement in line 412 ("..., as some of the results are still contradictory.").

Thanks again for the careful evaluation of our manuscript and the very kind overall comment.

Back to TopTop